BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
May 25, 2009
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Biovail, Cambridge Laboratories, GlaxoSmithKline sales and marketing update

Biovail will acquire worldwide rights to a portfolio of tetrabenazine products from Cambridge for $200 million up front, plus $30 million in two tranches over two years. The deal includes Xenazine/ Nitoman tetrabenazine, tetrabenazine CR ( BVF-018) and RUS350. Biovail...

Read the full 196 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >